{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:11:17Z","timestamp":1760044277749},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.pathol.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T21:52:01Z","timestamp":1650491521000},"page":"389-398","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Panel-based gene testing in myelodysplastic\/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement"],"prefix":"10.1016","volume":"54","author":[{"given":"Anoop K.","family":"Enjeti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishu","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Chee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Chyn","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Iland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.03.002_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"key":"10.1016\/j.pathol.2022.03.002_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_239083","article-title":"CHIP, CCUS, and other acronyms: definition, implications, and impact on practice","volume":"39","author":"DeZern","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.pathol.2022.03.002_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pathol.2021.01.003","article-title":"Myeloid somatic mutation panel testing in myeloproliferative neoplasms","volume":"53","author":"Ross","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2022.03.002_bib4","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cancers13092120","article-title":"Genetic aspects of myelodysplastic\/myeloproliferative neoplasms","volume":"13","author":"Palomo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2022.03.002_bib5","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2012.072538","article-title":"High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic\/myeloproliferative neoplasms","volume":"98","author":"Jeromin","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib6","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib7","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib8","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.03.002_bib9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib12","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A\u00a0phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib16","first-page":"162","article-title":"Promising results of a phase 1\/2 clinical trial of ruxolitinib in patients with chronic myelomonocytic leukemia","volume":"130","author":"Padron","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib17","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/10428194.2016.1217529","article-title":"Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap syndromes","volume":"58","author":"Sharma","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2022.03.002_bib19","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pathol.2022.03.002_bib21","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/ajh.26321","article-title":"Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes","volume":"96","author":"Martin","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.03.002_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.humpath.2018.10.026","article-title":"Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis","volume":"85","author":"Hu","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2022.03.002_bib26","doi-asserted-by":"crossref","first-page":"95e1","DOI":"10.1016\/j.bbmt.2020.10.007","article-title":"Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"27","author":"Gagelmann","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.pathol.2022.03.002_bib27","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.3324\/haematol.2018.208082","article-title":"Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation","volume":"104","author":"Patnaik","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib28","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-018-0050-z","article-title":"Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective","volume":"32","author":"Than","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2022.03.002_bib30","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.pathol.2022.03.002_bib32","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib34","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.03.002_bib35","first-page":"e414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cureus"},{"key":"10.1016\/j.pathol.2022.03.002_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib37","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib39","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.26090","article-title":"Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \"2021 update on diagnosis, risk-stratification, and management\"","volume":"96","author":"Patnaik","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib43","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib44","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.03.002_bib45","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.03.002_bib47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ajh.24038","article-title":"Refractory anemia with ring sideroblasts and RARS with thrombocytosis","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib48","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.03.002_bib49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib50","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.03.002_bib51","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/leu.2016.216","article-title":"Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis","volume":"30","author":"Patnaik","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib53","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib54","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib55","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1038\/s41375-021-01258-6","article-title":"Genomic stratification of myelodysplastic\/myeloproliferative neoplasms, unclassifiable: sorting through the unsorted","volume":"35","author":"Mangaonkar","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jmoldx.2016.05.006","article-title":"Rapid molecular profiling of myeloproliferative neoplasms using targeted exon resequencing of 86 genes involved in JAK-STAT signaling and epigenetic regulation","volume":"18","author":"Magor","year":"2016","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.pathol.2022.03.002_bib57","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1002\/acg2.48","article-title":"Advances in chronic myelomonocytic leukemia and future prospects: lessons learned from precision genomics","volume":"2","author":"Mangaonkar","year":"2019","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.pathol.2022.03.002_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2018.07.013","article-title":"Incidence and survival of therapy related myeloid neoplasm in United States","volume":"71","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2022.03.002_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy related-chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib60","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","article-title":"The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution","volume":"33","author":"Singhal","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib61","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib62","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification\u2014an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jmoldx.2018.07.002","article-title":"Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the association for molecular pathology","volume":"20","author":"McClure","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.pathol.2022.03.002_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ejh.12223","article-title":"Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic\/myeloproliferative neoplasms","volume":"92","author":"Fu","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2022.03.002_bib66","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib67","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.03.002_bib68","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.pathol.2022.03.002_bib69","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2022.03.002_bib70","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2020005488","article-title":"Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes","volume":"136","author":"Nagata","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib71","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood.2020008742","article-title":"Human and artificial intelligence to illuminate MDS","volume":"136","author":"Haferlach","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.03.002_bib72","article-title":"Next-generation diagnostics for precision oncology: preanalytical considerations, technical challenges, and available technologies","volume":"7","author":"Walter","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.pathol.2022.03.002_bib73","doi-asserted-by":"crossref","first-page":"958","DOI":"10.5858\/arpa.2015-0507-RA","article-title":"Next-generation sequencing informatics: challenges and strategies for implementation in a clinical environment","volume":"140","author":"Roy","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2022.03.002_bib74","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1182\/bloodadvances.2020002997","article-title":"Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects","volume":"4","author":"Eckardt","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2022.03.002_bib75","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2022.03.002_bib77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2018.07.010","article-title":"Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts","volume":"71","author":"Mangaonkar","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2022.03.002_bib78","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2022.03.002_bib79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:39:57Z","timestamp":1710509997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522001222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0031302522001222"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.03.002","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panel-based gene testing in myelodysplastic\/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}